The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to The Harvard Drug Group, L.L.C., a subsidiary of Cardinal Health, Inc., for the supply of Bupropion Hydrochloride (HCL) Tablets in 100mg and 75mg dosages. The contract, valued at $2,936,792.25, has a base period of performance from March 1, 2025, to February 28, 2026, with four one-year option periods. The contracted items will be distributed through the VA's and Department of Defense's Pharmaceutical Prime Vendor Programs, ensuring a reliable supply of these medications to various federal healthcare facilities, including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The solicitation was issued in commercial item format under FAR Part 12 and was not set-aside. The estimated annual usage is 51,786 bottles of 100mg tablets and 107,205 bottles of 75mg tablets. This contract award exemplifies The Harvard Drug Group's position as a key player in the federal government's pharmaceutical supply chain, leveraging its extensive resources and expertise to meet the diverse medication needs of various government healthcare providers.
In addition, Cardinal Health, Inc. holds a significant IDC with the VA Veterans Health Administration for the provision of radiopharmaceutical products to support medical imaging procedures within the VA healthcare system. This single-award contract, valued at $773,677.24, highlights Cardinal Health's specialized capabilities in handling and distributing time-sensitive, radioactive medical products crucial for diagnostic imaging in VA medical facilities. The contract's structure allows the VA to ensure a reliable supply of these essential but short-lived medical tracers, supporting its mission to provide comprehensive healthcare services to veterans.
Generated 1/1/25, 9:04 AM